{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T10:58:30Z","timestamp":1722941910761},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2006,2,6]],"date-time":"2006-02-06T00:00:00Z","timestamp":1139184000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"published-print":{"date-parts":[[2006,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Systemic inflammation is associated with various complications in chronic obstructive pulmonary disease including weight loss, cachexia, osteoporosis, cancer and cardiovascular diseases. Inhaled corticosteroids attenuate airway inflammation, reduce exacerbations, and improve mortality in chronic obstructive pulmonary disease. Whether inhaled corticosteroids by themselves or in combination with a long-acting \u03b2<jats:sub>2<\/jats:sub>-adrenoceptor agonist repress systemic inflammation in chronic obstructive pulmonary disease is unknown. The Advair Biomarkers in COPD (ABC) study will determine whether the effects of inhaled corticosteroids alone or in combination with a long-acting \u03b2<jats:sub>2<\/jats:sub>-adrenoceptor agonist reduce systemic inflammation and improve health status in patients with chronic obstructive pulmonary disease.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods\/Design<\/jats:title>\n            <jats:p>After a 4-week run-in phase during which patients with stable chronic obstructive pulmonary disease will receive inhaled fluticasone (500 micrograms twice daily), followed by a 4-week withdrawal phase during which all inhaled corticosteroids and long acting \u03b2<jats:sub>2<\/jats:sub>-adrenoceptor agonists will be discontinued, patients will be randomized to receive fluticasone (500 micrograms twice daily), fluticasone\/salmeterol combination (500\/50 micrograms twice daily), or placebo for four weeks. The study will recruit 250 patients across 11 centers in western Canada. Patients must be 40 years of age or older with at least 10 pack-year smoking history and have chronic obstructive pulmonary disease defined as forced expiratory volume in one second to vital capacity ratio of 0.70 or less and forced expiratory volume in one second that is 80% of predicted or less. Patients will be excluded if they have any known chronic systemic infections, inflammatory conditions, history of previous solid organ transplantation, myocardial infarction, or cerebrovascular accident within the past 3 months prior to study enrolment. The primary end-point is serum C-reactive protein level. Secondary end-points include circulating inflammatory cytokines such as interleukin-6 and interleukin-8 as well as health-related quality of life and lung function.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Discussion<\/jats:title>\n            <jats:p>If inhaled corticosteroids by themselves or in combination with a long-acting \u03b2<jats:sub>2<\/jats:sub>-adrenoceptor agonist could repress systemic inflammation, they might greatly improve clinical prognosis by reducing various complications in chronic obstructive pulmonary disease.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-2466-6-3","type":"journal-article","created":{"date-parts":[[2006,2,10]],"date-time":"2006-02-10T07:15:12Z","timestamp":1139555712000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Can inhaled fluticasone alone or in combination with salmeterol reduce systemic inflammation in chronic obstructive pulmonary disease? \u2013 study protocol for a randomized controlled trial [NCT00120978]"],"prefix":"10.1186","volume":"6","author":[{"given":"Don D","family":"Sin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SF Paul","family":"Man","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darcy D","family":"Marciniuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gordon","family":"Ford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"FitzGerald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ernest","family":"York","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajesh R","family":"Mainra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Warren","family":"Ramesh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lyle S","family":"Melenka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Wilde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert L","family":"Cowie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dave","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roxanne","family":"Rousseau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the ABC (Advair, Biomarkers in COPD) Investigators","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2006,2,6]]},"reference":[{"issue":"349","key":"42_CR1","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1016\/S0140-6736(96)07492-2","volume":"24","author":"CJ Murray","year":"1997","unstructured":"Murray CJ, Lopez AD: Alternative projections of mortality and disability by cause 1990\u20132020: Global Burden of Disease Study. Lancet. 1997, 24 (349): 1498-1504. 10.1016\/S0140-6736(96)07492-2.","journal-title":"Lancet"},{"key":"42_CR2","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1001\/jama.285.5.535","volume":"285","author":"CM Michaud","year":"2001","unstructured":"Michaud CM, Murray CJ, Bloom BR: Burden of disease \u2013 implications for future research. JAMA. 2001, 285: 535-539. 10.1001\/jama.285.5.535.","journal-title":"JAMA"},{"key":"42_CR3","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1136\/thx.2004.037135","volume":"60","author":"S Wasswa-Kintu","year":"2005","unstructured":"Wasswa-Kintu S, Gan WQ, Man SF, Pare PD, Sin DD: Relationship between reduced forced expiratory volume in one second and the risk of lung cancer: a systematic review and meta-analysis. Thorax. 2005, 60: 570-575. 10.1136\/thx.2004.037135.","journal-title":"Thorax"},{"key":"42_CR4","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1378\/chest.127.6.1952","volume":"127","author":"DD Sin","year":"2005","unstructured":"Sin DD, Wu L, Man SF: The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literature. Ches. 2005, 127: 1952-1959. 10.1378\/chest.127.6.1952.","journal-title":"Ches"},{"key":"42_CR5","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S0140-6736(04)16900-6","volume":"364","author":"JC Hogg","year":"2004","unstructured":"Hogg JC: Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet. 2004, 364: 709-721. 10.1016\/S0140-6736(04)16900-6.","journal-title":"Lancet"},{"key":"42_CR6","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1136\/thx.2003.019588","volume":"59","author":"WQ Gan","year":"2004","unstructured":"Gan WQ, Man SF, Senthilselvan A, Sin DD: Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax. 2004, 59: 574-580. 10.1136\/thx.2003.019588.","journal-title":"Thorax"},{"key":"42_CR7","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1183\/09031936.03.00405703","volume":"21","author":"AG Agusti","year":"2003","unstructured":"Agusti AG, Noguera A, Sauleda J, Sala E, Pons J, Busquets X: Systemic effects of chronic obstructive pulmonary disease. Eur Respir J. 2003, 21: 347-360. 10.1183\/09031936.03.00405703.","journal-title":"Eur Respir J"},{"key":"42_CR8","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1136\/thorax.57.12.1067","volume":"57","author":"EF Wouters","year":"2002","unstructured":"Wouters EF: Chronic obstructive pulmonary disease. 5: systemic effects of COPD. Thorax. 2002, 57: 1067-1070. 10.1136\/thorax.57.12.1067.","journal-title":"Thorax"},{"key":"42_CR9","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1056\/NEJM199503303321307","volume":"332","author":"PJ Barnes","year":"1995","unstructured":"Barnes PJ: Inhaled glucocorticoids for asthma. N Engl J Med. 1995, 332: 868-875. 10.1056\/NEJM199503303321307.","journal-title":"N Engl J Med"},{"key":"42_CR10","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1001\/jama.290.17.2301","volume":"290","author":"DD Sin","year":"2003","unstructured":"Sin DD, McAlister FA, Man SF, Anthonisen NR: Contemporary management of chronic obstructive pulmonary disease: scientific review. JAMA. 2003, 290: 2301-2312. 10.1001\/jama.290.17.2301.","journal-title":"JAMA"},{"key":"42_CR11","doi-asserted-by":"publisher","first-page":"579","DOI":"10.2165\/00003495-200565050-00001","volume":"65","author":"SF Man","year":"2005","unstructured":"Man SF, Sin DD: Inhaled corticosteroids in chronic obstructive pulmonary disease: is there a clinical benefit?. Drugs. 2005, 65: 579-591. 10.2165\/00003495-200565050-00001.","journal-title":"Drugs"},{"key":"42_CR12","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1136\/thx.2005.045385","volume":"60","author":"DD Sin","year":"2005","unstructured":"Sin DD, Wu L, Anderson J, Anthonisen N, Buist AS, Burge PS, Calverley P, Connett J, Lindmark B, Pauwels R, Postma D, Soriano J, Szafranski W, Vestbo J: Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Thorax. 2005, 60: 922-927. 10.1136\/thx.2005.045385.","journal-title":"Thorax"},{"key":"42_CR13","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1136\/bmj.320.7245.1297","volume":"320","author":"PS Burge","year":"2000","unstructured":"Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK: Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ. 2000, 320: 1297-1303. 10.1136\/bmj.320.7245.1297.","journal-title":"BMJ"},{"key":"42_CR14","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1161\/01.CIR.0000056767.69054.B3","volume":"107","author":"DD Sin","year":"2003","unstructured":"Sin DD, Man SF: Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation. 2003, 107: 1514-1519. 10.1161\/01.CIR.0000056767.69054.B3.","journal-title":"Circulation"},{"key":"42_CR15","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1164\/rccm.200404-543OC","volume":"170","author":"DD Sin","year":"2004","unstructured":"Sin DD, Lacy P, York E, Man SF: Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2004, 170: 760-765. 10.1164\/rccm.200404-543OC.","journal-title":"Am J Respir Crit Care Med"},{"key":"42_CR16","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1471-2466-5-3","volume":"5","author":"WQ Gan","year":"2005","unstructured":"Gan WQ, Man SF, Sin DD: Effects of inhaled corticosteroids on sputum cell counts in stable chronic obstructive pulmonary disease: a systematic review and a meta-analysis. BMC Pulm Med. 2005, 5: 3-10.1186\/1471-2466-5-3.","journal-title":"BMC Pulm Med"},{"key":"42_CR17","volume-title":"Thorax","author":"VM Pinto-Plata","year":"2005","unstructured":"Pinto-Plata VM, Mullerova H, Toso JF, Feudjo-Tepie M, Soriano JB, Vessey RS, Celli BR: C-reactive protein in patients with COPD, control smokers, and nonsmokers. Thorax. 2005, [http:\/\/thorax.bmjjournals.com\/cgi\/rapidpdf\/thx.2005.042200v1]"},{"key":"42_CR18","doi-asserted-by":"publisher","first-page":"12933","DOI":"10.1074\/jbc.274.18.12933","volume":"274","author":"O Eickelberg","year":"1999","unstructured":"Eickelberg O, Pansky A, Mussmann R, Bihl M, Tamm M, Hildebrand P, Perruchoud AP, Roth M: Transforming growth factor-beta1 induces interleukin-6 expression via activating protein-1 consisting of JunD homodimers in primary human lung fibroblasts. J Biol Chem. 1999, 274: 12933-12938. 10.1074\/jbc.274.18.12933.","journal-title":"J Biol Chem"},{"key":"42_CR19","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1164\/rccm.200408-1041OC","volume":"172","author":"OS Usmani","year":"2005","unstructured":"Usmani OS, Ito K, Maneechotesuwan K, Ito M, Johnson M, Barnes PJ, Adcock IM: Glucocorticoid receptor nuclear translocation in airway cells after inhaled combination therapy. Am J Respir Crit Care Med. 2005, 172: 704-712. 10.1164\/rccm.200408-1041OC.","journal-title":"Am J Respir Crit Care Med"},{"key":"42_CR20","first-page":"A127","volume":"2","author":"J Zhu","year":"2005","unstructured":"Zhu J, Qiu Y, Barnes NC, Johnson M, Pavord I, Jeffery PK: The effect of salmeterol\/fluticasone propionate on pro-inflammatory gene expression in COPD. Proceedings of the American Thoracic Society. 2005, 2: A127-","journal-title":"Proceedings of the American Thoracic Society"},{"key":"42_CR21","doi-asserted-by":"publisher","first-page":"A132","DOI":"10.1513\/pats.200502-015AW","volume":"2","author":"Y Qiu","year":"2005","unstructured":"Qiu Y, Parker D, Barnes NC, Johnson M, Pavord I, Jeffrey P: The effect of salmeterol\/fluticasone propionate on eosinophils and mast cells in COPD. Proceedings of the American Thoracic Society. 2005, 2: A132-10.1513\/pats.200502-015AW.","journal-title":"Proceedings of the American Thoracic Society"},{"key":"42_CR22","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/S0140-6736(97)03471-5","volume":"351","author":"PL Paggiaro","year":"1998","unstructured":"Paggiaro PL, Dahle R, Bakran I, Frith L, Hollingworth K, Efthimiou J: Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group. Lancet. 1998, 351: 773-780. 10.1016\/S0140-6736(97)03471-5.","journal-title":"Lancet"},{"key":"42_CR23","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1155\/2003\/861521","volume":"10","author":"DE O'Donnell","year":"2003","unstructured":"O'Donnell DE, Hernandez P, Aaron S, Bourbeau J, Marciniuk D, Hodder R, Balter M, Ford G, Gervais A, Goldstein R, Maltais F, Road J, McKay V, Schenkel J, Canadian Thoracic Society: Canadian Thoracic Society COPD Guidelines: summary of highlights for family doctors. Can Respir J. 2003, 10: 183-185.","journal-title":"Can Respir J"},{"key":"42_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1183\/09031936.03.00063703","volume":"22","author":"LM Fabbri","year":"2003","unstructured":"Fabbri LM, Hurd SS, GOLD Scientific Committee: Global Strategy for the Diagnosis, Management and Prevention of COPD: 2003 update. Eur Respir J. 2003, 22: 1-2. 10.1183\/09031936.03.00063703.","journal-title":"Eur Respir J"},{"key":"42_CR25","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1164\/ajrccm\/136.5.1285","volume":"136","author":"American Thoracic Society","year":"1987","unstructured":"American Thoracic Society: Standardization of spirometry \u2013 1987 update. Am Rev Respir Dis. 1987, 136: 1285-1298.","journal-title":"Am Rev Respir Dis"},{"key":"42_CR26","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1164\/ajrccm\/145.6.1321","volume":"145","author":"PW Jones","year":"1992","unstructured":"Jones PW, Quirk FH, Baveystock CM, Littlejohns P: A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis. 1992, 145: 1321-1327.","journal-title":"Am Rev Respir Dis"},{"key":"42_CR27","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1183\/09031936.05.00029705","volume":"26","author":"I Horvath","year":"2005","unstructured":"Horvath I, Hunt J, Barnes PJ, Alving K, Antczak A, Baraldi E, Becher G, van Beurden WJ, Corradi M, Dekhuijzen R, Dweik RA, Dwyer T, Effros R, Erzurum S, Gaston B, Gessner C, Greening A, Ho LP, Hohlfeld J, Jobsis Q, Laskowski D, Loukides S, Marlin D, Montuschi P, Olin AC, Redington AE, Reinhold P, van Rensen EL, Rubinstein I, Silkoff P, Toren K, Vass G, Vogelberg C, Wirtz H, ATS\/ERS Task Force on Exhaled Breath Condensate: Exhaled breath condensate: methodological recommendations and unresolved questions. Eur Respir J. 2005, 26: 523-548. 10.1183\/09031936.05.00029705.","journal-title":"Eur Respir J"},{"key":"42_CR28","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/S0954-6111(03)00035-0","volume":"97","author":"M Tsoumakidou","year":"2003","unstructured":"Tsoumakidou M, Tzanakis N, Siafakas NM: Induced sputum in the investigation of airway inflammation of COPD. Respir Med. 2003, 97: 863-871. 10.1016\/S0954-6111(03)00035-0.","journal-title":"Respir Med"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2466-6-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2466-6-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2466-6-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2466-6-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T22:26:30Z","timestamp":1630448790000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/1471-2466-6-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,2,6]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,12]]}},"alternative-id":["42"],"URL":"https:\/\/doi.org\/10.1186\/1471-2466-6-3","relation":{},"ISSN":["1471-2466"],"issn-type":[{"type":"electronic","value":"1471-2466"}],"subject":[],"published":{"date-parts":[[2006,2,6]]},"assertion":[{"value":"25 November 2005","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2006","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2006","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"3"}}